English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Knee osteoarthritis (OA) has been demonstrated in cadaver and radiographic studies to affect as many as 55 million patients over the age of 60 [1]. Patients with knee OA have pain, crepitus, loss of motion, and decreased ability to bear weight or ambulate. Limiting the ability to ambulate severely impairs the activities of daily living. Nonsurgical treatments for knee OA according to the American Academy of Orthopedic Surgeons (AAOS) include weight loss, gentle exercise, and the use of non-steroidal anti-inflammatory medications (NSAIDs). The surgical treatment for knee OA is total knee arthroplasty (TKA) [2]. The AAOS does not recommend knee arthroscopy or the use of any Hyaluronic Acid injections (HLA) [2].

Intra-Articular Injection of an Extracellular Vesicle Isolate Product to Treat Knee Osteoarthritis in an Athlete